SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.93-0.1%2:50 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: A.J. Mullen who wrote (51923)2/1/2022 3:19:44 PM
From: Art Bechhoefer  Read Replies (1) of 52153
 
Madrigal will probably get FDA approval on its NASH drug before competitors like Viking Therapeutics, which has a similar drug that requires much lower dosage for similar effectiveness. However, the fact that the Viking drug dosage is about one-fifth the dosage required by Madrigal makes VKTX look more attractive at its current price, even if Madrigal wins FDA approval earlier than Viking. Note that both drugs are similar in the way they work.

Art
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News